Janux Therapeutics Files 8-K for Regulation FD Disclosure

Ticker: JANX · Form: 8-K · Filed: Feb 26, 2024 · CIK: 1817713

Janux Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyJanux Therapeutics, Inc. (JANX)
Form Type8-K
Filed DateFeb 26, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

Topics: regulation-fd, compliance, corporate-filing

TL;DR

**Janux Therapeutics just filed an 8-K for Regulation FD, keeping the market informed.**

AI Summary

Janux Therapeutics, Inc. filed an 8-K on February 26, 2024, to disclose information under Regulation FD and provide financial statements and exhibits. The filing indicates a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The company, incorporated in Delaware with IRS Employer Identification No. 82-2289112, maintains its principal executive offices in San Diego, California.

Why It Matters

This filing ensures Janux Therapeutics, Inc. complies with SEC regulations regarding the disclosure of material non-public information, maintaining transparency for investors.

Risk Assessment

Risk Level: low — This 8-K is a routine compliance filing for Regulation FD and does not indicate any specific new risks.

Key Players & Entities

  • Janux Therapeutics, Inc. (company) — Registrant
  • Delaware (company) — State of Incorporation
  • 82-2289112 (dollar_amount) — IRS Employer Identification No.
  • February 26, 2024 (date) — Date of Report
  • San Diego, California (location) — Principal Executive Offices

FAQ

What is the purpose of this 8-K filing by Janux Therapeutics, Inc.?

The 8-K filing by Janux Therapeutics, Inc. is for Regulation FD Disclosure and to provide Financial Statements and Exhibits, pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on February 26, 2024.

What is the state of incorporation for Janux Therapeutics, Inc.?

Janux Therapeutics, Inc. is incorporated in Delaware.

What is the business phone number for Janux Therapeutics, Inc.?

The business phone number for Janux Therapeutics, Inc. is (858) 751-4493.

What is the Central Index Key (CIK) for Janux Therapeutics, Inc.?

The Central Index Key (CIK) for Janux Therapeutics, Inc. is 0001817713.

Filing Stats: 565 words · 2 min read · ~2 pages · Grade level 10.5 · Accepted 2024-02-26 16:23:58

Key Financial Figures

  • $0.001 — nge on which registered Common Stock, $0.001 par value per share JANX Nasdaq Glo

Filing Documents

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On February 26, 2024, the Company issued a press release announcing interim clinical data and is also making available a corporate presentation reporting interim clinical data. Copies of the press release and the corporate presentation are attached as Exhibits 99.1 and 99.2, respectively, to this report. The corporate presentation will also be available under the "Investors" section of the Company's website. The information in this Item 7.01 of this report (including Exhibits 99.1 and 99.2) is furnished and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information shall not be deemed incorporated by reference into any other filing with the Securities and Exchange Commission made by the Company, whether made before or after today's date, regardless of any general incorporation language in such filing, except as shall be expressly set forth by specific references in such filing.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated February 26, 2024. 99.2 Corporate Presentation. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). 1

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. JANUX THERAPEUTICS, INC. Date: February 26, 2024 By: /s/ David Campbell, Ph.D. David Campbell, Ph.D. President and Chief Executive Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.